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AbstrAct:
Akt (cellular homolog of murine thymoma virus akt8 oncogene) is an essential 
component of the PI3K (phosphatidylinositol 3-kinase) pathway. Its activity is 
stimulated by receptor tyrosine kinases and G-protein coupled receptors and plays a 
critical role in the regulation of cell proliferation, differentiation and apoptosis. A gain 
of function in Akt can lead to uncontrolled cell proliferation and resistance to apoptosis, 
both hallmarks of oncogenic transformation. In this communication, we have 
investigated the phosphorylation at the Akt residues T308, S473 and T450 and their 
roles in oncogenic transformation and signaling. We find that T450 phosphorylation 
has only a minimal part in these activities. In contrast, the phosphorylation of 
T308  and  of  S473  fulfills  essential,  distinct,  and  non-overlapping  functions  that 
we  define  with  inactivating  and  with  phosphomimetic  mutations  of  these  sites.
IntroductIon
AKT (cellular homolog of murine thymoma virus 
akt8 oncogene, synonym: PKB) [1-4] is a serine/threonine 
kinase of the AGC kinase family (PKA, PKG and PKC-
related kinases) [5]; it plays a critical role in cell growth [6], 
differentiation [7] and survival [8]. Major targets of AKT 
include the TSC1-TSC2 (tuberous sclerosis) complex 
which mediates TORC1 (target of rapamycin complex 1) 
activation [6], the forkhead transcription factors FOXO1 
(Forkhead box) and FOXO3a which regulate cell death, 
morphology and function as tumor suppressors [9-13], 
MDM2 (murine double minute) which regulates p53 
[14] and GSK3β (glycogen synthase kinase 3β) which 
modulates the metabolism of the cell [15]. 
 AKT is tightly regulated, because it controls a 
broad spectrum of pro-growth and pro-survival activities 
[16, 17]. PIP3, the product of PI3K (phosphatidylinositol 
3-kinase), is an essential mediator of the activation of 
AKT by PDK1 (3-phosphoinositide-dependent protein 
kinase-1) [17]. The PH (pleckstrin homology) domains 
of both PDK1 and AKT can bind to PIP3, and this co-
localization allows PDK1 to phosphorylate AKT at the 
catalytic phosphorylation site, T308 [17, 18]. AKT is 
also phosphorylated at the hydrophobic motif, S473, 
by TORC2 (target of rapamycin complex 2) and DNA-
PK (DNA-activated protein kinase) [11, 17, 19, 20] and 
possibly by rapamycin-insensitive TORC1 [21]. S473 
phosphorylation further increases enzymatic activity 
[22] and broadens substrate scope to include FOXO 
transcription factors and PRAS40 (proline-rich Akt 
substrate) which are not phosphorylated in the absence 
of S473 phosphorylation [11]. A third phosphorylation 
site on AKT has been identified at T450 [22]. This site 
is referred to as the turn phosphorylation site. It was 
previously thought to be a result of autophosphorylation, 
but more recent work has shown that its phosphorylation 
is controlled by TORC2 activity [23, 24]. This 
phosphorylation site is important in other AGC kinases, 
but the role in AKT signaling had not been determined.
AKT is also under the control of negative feedback 
loops. Activation of AKT leads to the activation of 
TORC1 and its downstream target p70S6K (p70 S6 
kinase). p70S6K phosphorylates IRS1 (insulin receptor 
substrate). This event lowers PI3K activity, attenuating 
the phosphorylation of AKT at T308 [25]. Another 
mechanism for controlling AKT depends on the 
modulation of TORC2 activity. TORC2 activity requires 
the intact and unphosphorylated TSC1-TSC2 complex 
which is disrupted by AKT phosphorylation [26]. This 
inhibition of TSC1-TSC2 leads to a decrease in S473 
phosphorylation. TORC1 and TORC2 activities are 
also suppressed by DEPTOR. Suppression of both TOR 
complexes leads to situations where DEPTOR can act Oncotarget 2011; 2:  467 - 476 468 www.impactjournals.com/oncotarget
either as a suppressor or activator of AKT [27]. These 
mechanisms assure stable self-attenuating signaling by 
Akt.
AKT is commonly activated in human cancers 
where it stimulates cell proliferation and survival [28, 29]. 
Aberrant, cancer-specific activation of AKT can be caused 
by several distinct mechanisms. Mutated or overexpressed 
receptor tyrosine kinases can stimulate the entire PI3K 
pathway. Mutations in both catalytic (p110) or regulatory 
(p85) subunits of PI3K or in PTEN (phosphatase and 
tensin homolog) can also generate elevated levels of PIP3, 
leading to constitutive activation of AKT. In some cases, 
AKT itself is constitutively active because of a mutation 
in the PH domain (E17K) [30] or, as in the case of the 
v-AKT of murine thymoma virus, fusion to viral Gag 
sequences that mediate membrane attachment [1]. The 
latent oncogenicity of AKT can also be revealed by fusing 
an amino terminal myristylation sequence to the protein, 
thus inducing constitutive, PIP3-independent membrane 
localization [31]. Alteration of the specificity of the PH 
domain towards the abundant PI(4,5)P2  is  sufficient  to 
lead to constitutive activation and oncogenicity of Akt 
suggesting that other mutations of the PH domain may 
occur [32]. 
We have systematically mutated the phosphorylation 
sites in AKT, T308, T450 and S473, to either alanine 
(A) which cannot be phosphorylated, or to aspartate 
(D) which also cannot be phosphorylated, but mimics 
phosphorylated serine. We have then determined the effect 
of the mutations on the oncogenic and signaling potentials 
of the protein.
MAterIAls And Methods.
Plasmids
  pBSfi-Akt  and  pBSfi-myr-Akt  of  mouse 
Akt1 have been previously described and contain a 
C-terminal HA tag [31]. These were mutated by site 
directed mutagenesis at T308, T450 and S473 with 
the following primers and their complement: T308D, 
“TGCCACTATGAAGGATTTCTGCGGAACGCCG”, 
T308A,“TGCCACTATGAAGGCATTCTGCGGAACG
CCG”, S473D,“CACTTCCCCCAGTTCGACTACTCA
GCCAGT GGC”, S473A, “CACTTCCCCCAGTTCGC 
CTACTCAGC CAGTGGC”, T450D, “CAGCTCAGATG
ATCACCATCGACCCGCCTGATCAAGATGACAG”,
 T450A, “CAGATGATCACCATCGCGCCGCCTGA
TCAAG”, MYR-G2A, “TATCGATAAGCTTATGGCG
AGCAGCAAGAGCAAGC”, R25A, ”CTTGAGGAG
GAAGTAGGCTGGCCGCCAGGTTTT”. The resulting 
plasmids were subcloned into the SfiI site of RCAS(A).
sfi. In the experiments described in this manuscript, AKT 
refers to the protein encoded by the mouse Akt1 gene.
Assays for oncogenic transformation
RCAS(A) constructs were transfected into chicken 
embryonic  fibroblasts  (CEF)  using  the  Lipofectamine 
2000. 24 hours after transfection, the growth medium 
was removed and replaced with a nutrient agar overlay. 
Additional nutrient agar was added every 3 days for 2 
weeks. The agar was removed and the cells stained using 
crystal violet.
Western blotting
RCAS(A) constructs were transfected into CEF 
using the polybrene/DMSO shock method [33]. CEF 
were cultured in cloning media for 3 passages during 
which time the virus infected all the cells as monitored by 
RCAS(A)-GFP control. Cells were lysed using CHAPS 
lysis buffer (50 mM TrisHCl (pH 7.5), 1 mM EDTA, 
0.3% (w/v) CHAPS, 1 mM sodium orthovanadate, 10 mM 
sodium β-glycerophosphate, 50 mM sodium fluoride, 5 
mM sodium pyrophosphate, 0.15 M NaCl, 0.1 mM PMSF 
and complete protease-inhibitor cocktail (1 tablet/50mL 
lysis buffer)). Protein lysates were collected, left on ice 
for 30 minutes and centrifuged at 16,000xg. Protein 
concentrations were measured using the BCA method. 
The protein concentrations were normalized to 15 µg 
per sample and separated on a 4-12% Bis-Tris Nupage 
Gel (Invitrogen, Carlsbad, CA) using a MOPS running 
buffer. Proteins were transferred to Millipore Immobilon 
P PVDF membranes. Membranes were blocked with 
5% BSA in TBS-T and probed using antibodies against 
p-T308-Akt (#9275), p-T450-Akt (#9267), p-S473-Akt 
(#9271), p-S6 (#2211), p-GSK3β (#9336), HA (#2367), 
actin (#4976), FOXO1 (#9462) (Cell Signaling, Danvers, 
MA). Membranes were rinsed three times with TBS-T and 
probed with goat anti-rabbit-HRP or goat anti-mouse-HRP 
as appropriate. The membranes were rinsed an additional 
three times and developed using SuperSignal West Pico 
ECL  substrate  and  recorded  using  a  Biorad  Chemidoc 
XRS camera.
results
Mutating AKt phosphorylation sites
The aim of this mutant analysis was to obtain 
comprehensive  data  on  the  significance  of  individual 
AKT phosphorylation sites for oncogenicity and for 
signaling. The mutations were introduced both into wild-
type AKT and into the constitutively active, myristylated 
AKT to identify activating as well as inactivating changes 
and to delineate the role of membrane localization in the 
functions of Akt. Wild-type and mutated AKT proteins Oncotarget 2011; 2:  467 - 476 469 www.impactjournals.com/oncotarget
were expressed as inserts in the avian retroviral vector 
RCAS [34], and all constructs included a C-terminal HA 
epitope tag for detection. Comparison between tagged 
and untagged versions of the same protein did not detect 
any tag-related functional differences. RCAS constructs 
were transfected into chicken embryo fibroblasts (CEF) 
using Lipofectamine 2000 ® (Invitrogen, Carlsbad, CA). 
Oncogenic activity was determined by enumerating foci 
of transformed cells on CEF monolayers. For the analysis 
of AKT-mediated signaling, cultures in which each cell 
expressed the transfected construct were harvested, and 
cell lysates from these harvests were used for Western 
blot analyses to verify the phosphorylation status of 
AKT and to determine signaling activity. For this latter 
purpose, GSK3β was probed as a direct AKT target, and 
phosphorylation of the ribosomal protein S6 was used as 
read-out for downstream signaling activity that proceeds 
through the TSC complex, RHEB (Ras homolog enriched 
in brain) and TORC1 to p70S6K. 
the catalytic phosphorylation site, t308
Phosphorylation of T308 is essential for catalytic 
activity of Akt. The active site of Akt is disordered in 
the absence of phosphorylation [35]. Phosphorylation 
of T308 allows the organization of a network of 
interactions including stabilization of the αC helix that is 
essential for the functioning of the catalytic domain and 
formation of the active site [35]. A mutation of this site 
is therefore expected to have a negative effect on AKT 
functions, and this is confirmed in the transformation and 
signaling studies (Table 1, Fig. 1). The non-myristylated 
T308D mutation shows an extremely low transforming 
activity, and the non-myristylated T308A is inactive 
in transformation assays. In the myristylated version, 
T308D significantly reduces transforming potential, and 
T308A completely abolishes it. This loss of activity is 
also reflected in reduced signaling. The non-myristylated 
T308 mutants do not change phosphorylation of GSK3β 
from the levels seen in wild-type AKT or control cells 
that have received empty vector, either in the presence or 
absence of serum. Phosphorylation of S6 is suppressed 
compared to wild-type AKT and is close to the levels 
seen with empty vector. In the myristylated versions of 
these mutations, T308D shows great loss in signaling 
to S6 in the presence or absence of serum and a minor 
reduction in GSK3β signaling that becomes evident in the 
presence of serum. The myristylated T308A mutant shows 
an even greater reduction of S6 signaling independent 
of serum. The enhanced phosphorylation of GSK3β 
by this mutant under conditions of serum starvation is 
surprising and puzzling, but may derive from an indirect 
Figure 1: Western blots of t308 catalytic phosphorylation site mutants. The T308 phosphorylation site was mutated to alanine 
(T308A) or aspartate (T308D) in both myristylated and wild-type constructs. Akt phosphorylation and the downstream targets, GSK3β and 
S6 ribosomal protein are shown. Actin was used as a loading control, and HA is used to detect the overexpressed constructs. The T308A 
mutation blocks downstream signaling. The T308D mutation generates an incomplete mimic of phosphoserine and results in decreased 
signaling of myr-Akt-T308D.Oncotarget 2011; 2:  467 - 476 470 www.impactjournals.com/oncotarget
effect of the mutant on the activation of endogenous Akt. 
S473 phosphorylation is slightly increased, however 
the catalytically important T308 phosphorylation is still 
low. This apparent enhancement of Akt signaling is lost 
upon serum stimulation and will therefore not affect 
transformation which takes place in the presence of 3% 
serum. The low oncogenic and signaling activity of the 
T308D mutants is largely a reflection of the incomplete 
mimicking of phospho-threonine by aspartate. These 
results support the conclusion that phosphorylation 
of T308 in AKT is essential and necessary for the cell-
transforming activity and for signaling.
the hydrophobic phosphorylation site, s473
The cell-transforming activities of the S473D and 
S473A mutations are shown in Table 1. Whereas the 
S473A mutant in the non-myristylated protein is inactive, 
the S473D mutant shows highly significant transforming 
activity. In the myristylated version, these mutations do 
not strongly affect the base levels of activity seen with 
the myristylated wild-type AKT. Both myristylated S473 
mutants remain strongly transforming. The signaling 
activity of the mutants is not fully in accord with the 
transforming activity (Fig. 2). The non-myristylated 
S473D, despite its transforming activity, shows only slightly 
elevated phosphorylation of AKT T308 in the presence, 
but not in the absence of serum, and does not significantly 
stimulate the phosphorylation of downstream targets 
GSK3β and S6 independent of growth factor availability. 
Under serum-starved conditions, the myristylated S473D 
mutant shows enhancement of phosphorylation on AKT 
T308 and S6, but not on GSK3β. In the presence of serum, 
there is no effect on AKT T308, but phosphorylation of 
S6 is further increased. The myristylated S473A mutant 
induces phosphorylation of AKT T308 in the presence or 
absence of serum. In the presence of serum, in agreement 
with its transforming activity, the myristylated S473A 
also strongly signals to S6. The observations on the non-
myristylated S473D mutant show that phosphorylation 
at this site can activate a latent oncogenicity. However, 
the persistent activities of the myristylated S473A mutant 
show that this phosphorylation is not essential for signaling 
through TORC1 or for oncogenicity that is activated by 
constitutive localization to a cellular membrane. 
The transformation by S473D raises the possibility of 
Akt activation by a mechanism analogous to the activation 
Table 1: Efficiencies of oncogenic transformation. 
The table lists the number of foci induced, standardized 
to 1 ng DNA. The standard error for these focus 
determinations is 6 %. All constructs are expressed in 
CEF with the RCAS vector.
Construct Foci/ng DNA
Vector only  0
AKT  0
myr-AKT  1700
AKT-T308D  5
AKT-T308A  0
myr-AKT-T308D  450
myr-AKT-T308A  0
AKT-S473D  500
AKT-S473A  0
myr-AKT-S473D  2400
myr-AKT-S473A  2000
Akt-R25A  0
Akt-R25A,S473D  28
AKT-T450D  12
AKT-T450A  20
myr-AKT-T450D  1700
myr-AKT-T450A  1300
Figure 2: Western blots of s473 hydrophobic motif phosphorylation site mutants. The T450 phosphorylation site was mutated 
to alanine (S473A) or aspartate (S473D) in both myristylated and wild-type constructs. Akt phosphorylation and the downstream targets, 
GSK3β and S6 ribosomal protein are shown. Actin was used as a loading control, and HA is used to detect the overexpressed constructs. 
The S473D mutation significantly enhances transformation by both the wild-type and myristylated constructs.Oncotarget 2011; 2:  467 - 476 471 www.impactjournals.com/oncotarget
of other AGC (cAMP-dependent protein kinase/protein 
kinase G/protein kinase C) kinases such as p70S6K 
or SGK [36, 37]. In these kinases, phosphorylation of 
the hydrophobic motif mediates the binding to PDK1, 
allowing phosphorylation of the catalytic site. This 
association is independent of PH domain binding. We 
therefore combined the PH domain-inactivating mutation 
R25A with S473D [31]. The combination of R25A with 
S473D strongly reduces the transforming ability of Akt, 
although it does not eliminate it. The residual transforming 
activity may reflect the direct interaction of PDK1 with 
the S473D mutant. However, the strong reduction of 
transforming potential indicates that the S473D mutation 
is still dependent upon membrane binding for activity.
the turn phosphorylation site, t450
T450 was mutated to A or D in both wild-type and 
myristylated AKT. The effect of the mutations of the wild-
type and myristylated proteins is minimal on signaling, 
shown in Figure 3, or transformation, summarized in Table 
1. A slight change in signaling is seen in the presence of 
serum and growth factors. The T450D mutation in wild-
type and in myristylated AKT leads to an enhanced 
phosphorylation of the S6 ribosomal protein, presumably 
mediated by an upregulation of signaling through 
TORC1. The elevated signaling activity characteristic 
of myristylated AKT is not affected by mutation of the 
T450 site. The T450A and T450D mutations also fail 
to inactivate the strong cell-transforming activity of 
myristylated AKT. Surprisingly, in the wild-type protein, 
these mutations induce a marginal, but clearly detectable 
transforming activity (Table 1). There is also slightly 
increased phosphorylation of GSK3β by the T450D 
mutation in the wild-type protein. Studies on other AGC 
kinases have implicated the turn phosphorylation site 
in the control of kinase activity, substrate scope and 
protein stability [23, 24].  However, the mutations of 
T450 do not substantially change cell transforming and 
signaling activities of Akt and do not have a strong effect 
on steady-state protein levels. We conclude that the turn 
phosphorylation site does not play a significant role in the 
control of Akt signaling and oncogenicity.
dIscussIon
In the standard progression of events leading to 
AKT activation, the PH domain binds to PIP3, facilitating 
association with PDK1. This leads to phosphorylation 
on T308 and an initial activation of catalytic activity. 
Separately, TORC2 is activated and phosphorylates 
AKT at S473, inducing an additional gain in the catalytic 
activity of AKT. Alternatively, TORC2, activated in 
response to growth factor signaling, phosphorylates AKT 
at S473 first, followed by the binding of phosphorylated 
hydrophobic motif to the PIF (protein kinase C-related 
Figure 3: Western blots of t450 turn motif phosphorylation site mutants. The T450 phosphorylation site was mutated to 
alanine (T450A) or aspartate (T450D) in both myristylated and wild-type constructs. Akt phosphorylation and the downstream targets, 
GSK3β and S6 ribosomal protein are shown. Actin was used as a loading control, and HA is used to detect the overexpressed constructs. 
Mutation of T450 did not block downstream signaling but may slightly enhance signaling induced by serum stimulation.Oncotarget 2011; 2:  467 - 476 472 www.impactjournals.com/oncotarget
Figure 4: summary of phosphorylation site mutations: effects on Akt-induced oncogenic transformation and signaling. 
Oncogenic transformation was arbitrarily graded as follows: ”-“ (<10 foci/ng DNA), “+” (10 to 50 foci/ng DNA), “++” (50 to 500 foci/
ng DNA),  “+++” (500 to 1999 foci/ng DNA) and “++++” (2000 and more foci/ng DNA). The density of the bands in the Western blots 
was similarly assessed as “-“ (no band), “+” (weak target phosphorylation), “++” (intermediate target phosphorylation), and “+++” (strong 
target phosphorylation). PH, pleckstrin homology domain; HM, hydrophobic motif.Oncotarget 2011; 2:  467 - 476 473 www.impactjournals.com/oncotarget
kinase 2-interacting fragment)-binding pocket of PDK1. 
Upon binding of Akt to PDK1, phosphorylation of AKT 
on T308 ensues. The two mechanisms are not mutually 
exclusive; the prevalence of one or the other may be 
context-dependent. Both mechanisms employ three basic 
components, membrane binding, PDK1 phosphorylation 
of T308 and TORC2 phosphorylation of S473. 
Membrane localization of AKT can occur in several 
ways. In response PIP3 produced by PI3K, AKT localizes 
to the membrane. Additionally, modification of AKT by 
myristylation, Gag-fusion or mutation of the PH domain 
can drive AKT to the membrane constitutively. All of these 
mechanisms result in phosphorylation and activation of 
AKT at both T308 and S473. PDK1 has a high affinity 
to membrane lipids, specifically those containing PIP3 but 
also PI(3,4)P2 and PI(4,5)P2. Consequently, even under 
quiescent conditions, a substantial fraction of PDK1 
remains membrane associated. If AKT is brought to the 
membrane, whether by myristylation, Gag fusion or PH 
domain mutation, AKT will be activated by virtue of this 
co-localization. It has been suggested that the PH domain 
serves as a mask of the T308 phosphorylation site [38, 39]. 
This arrangement would prevent the accidental activation 
of AKT in the event of a chance collision between PDK1 
and AKT. Interaction of the PH domain with lipid would 
open access for PDK1 to T308, and this conformational 
change appears to be a prerequisite to AKT activation. 
However, when myristylation mediates PH domain-
independent membrane localization, the frequency of 
encounters with PDK1 could be high enough to drive 
phosphorylation of T308. It is also possible that the 
attachment of a peptide to the N-terminus destabilizes the 
interaction of the PH domain with the catalytic domain. 
As yet there is no structure of the Akt protein showing 
the interaction of the PH domain and catalytic domain 
in the inactive protein. Mutation of the critical glycine 
of the myristylation tag to an alanine completely blocks 
transformation, suggesting that N-terminal additions 
do not inherently destabilize the inhibitory PH-domain 
conformation.
Mutation of AKT phosphorylation sites results in 
very different effects on oncogenicity and on signaling 
(Fig. 4). Not unexpectedly, the T308 site emerges as the 
most critical for these activities. We find that the T308D 
is an unsuitable substitution for the native phospho-
threonine. AKT can exist in multiple conformational 
states, catalytically active and inactive. AKT that is not 
phosphorylated at T308 is predominantly in the inactive 
state. Phosphorylation of T308 results in the formation 
of an ordered hydrogen bonding network between the 
catalytic N lobe and the activation loop. This hydrogen 
bonding network between the phosphate of the phospho-
threonine, histidine 195 and arginine 274 orders the active 
site of the enzyme, allowing for both ATP and substrate to 
bind. The substitution of aspartate for threonine does not 
bring the appropriate number of hydrogen bond acceptors 
or the correct conformation (carboxylic acids being 
trigonal planar vs phosphates being tetrahedral) into this 
critical organizing structure. The imperfect mimic of the 
phosphorylated state results in a partial activation of the 
protein, but the activity is less than the native structure. 
Thus, the substitution causes a loss of transformation 
and signaling activity in myr-T308D as compared to the 
parent myristylated protein. The transforming potential of 
the non-myristylated T308D mutant is barely detectable. 
This imperfect mimicry also leads to decreased 
activity of myr-Akt-T308D-S473D as compared with 
myr-Akt and myr-Akt-S473D and decreased activity of 
Akt-T308D-S473D as compared with Akt-S473D (data 
not shown). The use of phospho-mimetic aspartate at these 
sites should be discouraged as they do not recapitulate a 
fully active form of Akt.
Phosphorylation of S473 is required for maximal 
activation of AKT. In the wild-type AKT protein, this 
phosphorylation leads to further stabilization of the N-lobe 
of the kinase. The entire regulatory domain wraps around 
the AKT kinase with the phosphorylated S473 nestled 
atop the α helix. This stabilization pushes the equilibrium 
toward the active conformation, increasing AKT catalytic 
activity by approximately 10 fold [22]. The interaction is 
simulated quite well by the S473D mutation. This mutation 
alone is sufficient to render wild type AKT oncogenic. 
The S473D mutant of AKT has been previously shown 
to be a better substrate for PDK1 through direct physical 
interaction with the PIF-binding pocket on PDK1 [40]. 
This mechanism is central in the activation of other AGC 
kinases, but its need is bypassed in AKT by PIP3 mediated 
membrane  interaction.  However,  we  find  that  the  PH 
domain still plays a significant role in the activation of 
S473D as the introduction of the R25A mutation blocks 
most of the transforming activity of S473D. These results 
support the hypothesis that the PH domain is not only 
responsible for localization to the membrane but also 
controls the accessibility of the T308 site [38, 41].
The limiting factor in downstream signaling 
from serum-stimulated or myristylated Akt is probably 
the phosphorylation of S473. The level of S473 
phosphorylation is controlled by TORC2 and PHLPP. The 
phosphomimetic S473D mutation eliminates this control 
and thus permits enhanced signaling to S6.
Despite this well documented role of S473 
phosphorylation,  we  find  that  it  may  not  be  necessary 
for transformation. In the myristylated construct, both 
S473D and S473A mutations are active and transform 
with comparable efficiency. Myristylated AKT is highly 
phosphorylated at both T308 and S473, and S473D does 
not further increase the transformation induced by the 
myristylated protein. However, the strong transforming 
activity of the myristylated S473A mutant suggests that 
S473 phosphorylation is not essential for the oncogenic 
activity of AKT. S473 has been previously shown to control 
two separate aspects of AKT. First, S473 phosphorylation Oncotarget 2011; 2:  467 - 476 474 www.impactjournals.com/oncotarget
causes the hydrophobic motif to bind to the αC helix in 
the catalytic domain of AKT and to further stabilize the 
active form of the kinase [35]. Second, S473 results in a 
broadening of the substrate scope of AKT to include more 
diverse targets such as the forkhead transcription factors 
and PRAS40 [11]. We find that under the conditions of 
our assays, FOXO1 and FOXO3a are destabilized by myr-
AKT-S473A (Supplemental Figure 1). This is in contrast 
to previous experiments which used knockout of TORC2 
components to limit S473 phosphorylation [11]. However, 
in our experiments AKT is overexpressed, and the higher 
levels of the enzyme may be adequate to phosphorylate 
FOXO despite reduced catalytic activity. 
In the T308D and myr-T308D-expressing cells, the 
protein detected by the phospho-T308 Akt antibody is 
likely the endogenous wild-type protein. This interpretation 
is suggested by the observation that both T308D and 
myr-T308D have similar expression by HA blotting, 
but have drastically different phospho-T308 reactivity. 
The HA blotting also documents the expected mobility 
shift from the myristylation; that shift is absent from the 
phospho-T308 blot. This suggests that T308D constructs 
protect endogenous Akt from dephosphorylation by PP2A 
rather than directly participating in downstream signaling.
Our experiments with the T450 mutation suggest 
that this site plays a minimal role in the transforming and 
signaling activities of AKT. The T450 phosphorylation 
site is disordered in all the structures of AKT obtained 
so far, but a model of the potential structure has been 
generated [42]. Knockout of TORC2 components 
causes a loss of phosphorylation of T450, but it is not 
clear whether TORC2 phosphorylates T450 directly 
or controls the activity of another kinase [43]. These 
experiments also showed that in the absence of TORC2, 
AKT is unstable and readily degraded. We did not note 
a significant elevation or reduction of AKT levels with 
the T450D or T450A mutants in our experiments. It is 
possible that overexpression masks a rapid turnover of the 
protein. T450 has also been reported to be a substrate of 
JNK (c-jun N-terminal kinase) [44]. In those experiments 
it was found that T450 phosphorylation can lead to 
increased T308 and S473 phosphorylation as well as AKT 
activity and stability. Our results show that there is a slight 
activation of oncogenic activity, but it is much less than in 
other strongly transforming constructs.
There are significant differences in the expression 
levels  of  several Akt  constructs.  Specifically  myr-Akt-
T308D and myr-Akt-T308A are expressed at a much higher 
level than myr-Akt without mutation. These changes 
in protein expression can be attributed to previously 
identified changes in Akt protein stability [45-47]. In a 
previous publication, we have also described enhanced 
proteolytic cleavage of membrane bound and strongly 
transforming forms of Akt [32]. These observations 
suggest the existence of a negative feedback loop that is 
triggered by hyperactive Akt and is capable of regulating 
Akt at the level of protein expression.
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